Treatment of malaria ( Plasmodium vivax and Plasmodium ovale), in combination with chloroquineTreatment of Pneumocystis jiroveci pneumonia (PCP), in combination with clindamycin
DOSE IN NORMAL RENAL FUNCTION
Malaria: 15–30 mg once daily for 14 days PCP: 30 mg once daily
20 to 50     : Dose as in normal renal function
10 to 20     : Dose as in normal renal function
<10           : Dose as in normal renal function
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unknown dialysability. Dose as in normal renal function
HD                     :Not dialysed. Dose as in normal renal function
HDF/high flux   :Unknown dialysability. Dose as in normal renal function
CAV/VVHD      :Unknown dialysability. Dose as in normal renal function
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Antimalarials: avoid concomitant use with artemether/lumefantrine
ADMINISTRATION
Reconstition
–
Route
Oral
Rate of Administration
–
Comments
–
OTHER INFORMATION
Primaquine base 7.5 mg is approximately equivalent to 13.2 mg primaquine phosphateMajor metabolite, 8-(3-carboxyl-1- methylpropylamino)-6-methoxyquinolone, possesses less antimalarial activity than the parent compound
Contraindicated in acutely ill patients with rheumatoid arthritis or SLE – increased risk of developing granulocytopeniaRisk of haemolytic anaemia in patients with G-6-PD deficiency; haemolysis generally appears 2–3 days after primaquine administration. Risk of methaemoglobinaemia at high doses